Navigation Links
Lotus Pharmaceuticals Announces Conference Call to Discuss Third Quarter 2010 Financial Results
Date:11/10/2010

BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it will hold a conference call to discuss financial results for the third quarter ended September 30, 2010. The conference call is scheduled for November 11, 2010 at 1:00 p.m. Eastern time (10:00 a.m. Pacific).

To participate in the call, please dial (877) 941-1430, or (480) 629-9667 for international calls, approximately 10 minutes prior to the scheduled start time. Interested parties can also listen via a live Internet webcast, which can be found at http://ViaVid.net.

A replay of the call will be available for two weeks from 4:00 p.m. EST on November 11, 2010 until 11:59 p.m. EST on November 25, 2010. The number for the replay is (877) 870-5176, or (858) 858-384-5517 for international calls; the pass code for the replay is 4385128.

About Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking StatementsExcept for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.Contacts:At the Company:Xing Shen, Ph.D.VP of Corporate DevelopmentLotus Pharmaceuticals, Inc.Ph: 415-690-7688Email: shen@lotuspharma.comWeb: http://www.lotuspharma.comInvestor Relations:Dave Gentry, U.S.RedChip Companies, Inc.Tel: +1-800-733-2447, Ext. 104Email: info@redchip.comJing Zhang, ChinaRedChip Beijing Representative OfficeTel: +86 10-8591-0635Web: http://www.RedChip.com
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
2. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
3. Lotus Pharmaceuticals Announces Two Senior Management Appointments
4. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
5. Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I
6. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
7. Lotus Completed R-Bambuterols Pilot Scale Production for Clinical Trials
8. Lotus Pharmaceuticals Terminates SEDA
9. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
10. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
11. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , Isansys  Lifecare, a new generation ... Engine wireless patient monitoring platform, as it ships more systems ... , Scotland and Norway ... generation system, launched earlier this year, is now being used in ... , This new technology significantly enhances the user experience ...
(Date:5/31/2016)... 2016 194 Mitgliedsstaaten ... Eliminierung von viraler Hepatitis    Am ... eingegangen, virale Hepatitis bis 2030 zu eliminieren. ... Assembly haben sich die Staaten einstimmig dafür entschieden, ... Viral Hepatitis Strategy) zu verabschieden, was das bisher ...
(Date:5/31/2016)... May 31, 2016 RnRMarketResearch.com adds ... with comparative analysis of Asthma therapy at various stages, ... route of administration (RoA) and molecule type, along with ... also reviews key players involved in the therapeutic development ... projects. Complete report on H1 2016 pipeline ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... technology solutions to the healthcare industry, The University of Scranton is adding a ... accelerated path to a career in rapidly growing field of healthcare information. ...
(Date:5/30/2016)... ... ... As the CDC relaxes its stance on traditional No-Nit policies, parents wonder ... lice free. , According to a May 26 article from news source ... classroom despite the fact that they may be harboring an infestation. Previous No-Nit policies ...
(Date:5/30/2016)... , ... May 30, 2016 , ... ... 6th, while Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts ... annual overnight summer camp offers families and children a fun and unique experience ...
(Date:5/29/2016)... North Carolina (PRWEB) , ... May 29, 2016 , ... ... Now, via Amazon.com, their new KlipPro KP-240L clipper is available to the public. This ... which is substantially wider than the average clipper. , Everything about this product ...
(Date:5/28/2016)... ... ... "Color Grading media can be time consuming but with FCPX LUT Night ... Austin - CEO of Pixel Film Studios. , With the FCPX LUT Night ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ...
Breaking Medicine News(10 mins):